Media coverage about Horizon Therapeutics (NASDAQ:HPTX) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Horizon Therapeutics earned a daily sentiment score of 0.25 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.0331317480287 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Horizon Therapeutics (HPTX) remained flat at $$45.99 during trading on Monday. Horizon Therapeutics has a fifty-two week low of $20.23 and a fifty-two week high of $46.96.
TRADEMARK VIOLATION NOTICE: This piece was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://ledgergazette.com/2017/12/11/horizon-therapeutics-hptx-earns-media-sentiment-rating-of-0-25.html.
About Horizon Therapeutics
Horizon Therapeutics, Inc, formerly Hyperion Therapeutics, Inc, is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder.
Receive News & Ratings for Horizon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.